Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The updates include new information on optimizing therapy, dealing with virological failure and managing opportunistic infections.
HIV treatment usually requires daily pills, but longer-acting regimens are gaining ground.
Findings confirm that Trogarzo maintains viral load suppression for nearly 10 years.
Extended follow-up confirms that the long-acting monoclonal antibody works well for people with highly resistant HIV.
Researchers are surprised and concerned that a strain of HIV that is so broadly resistant to treatment even has the capacity to transmit.
Expanded access study confirms the long-acting monoclonal antibody works well in people with extensive prior treatment.
A clinical trial has confirmed that new HIV treatment Trogarzo suppresses one’s viral load.
The Conference on Retroviruses and Opportunistic Infections in Seattle saw many important studies that are advancing the fight against HIV.
Researchers followed a small group of people with highly drug-resistant virus taking injectable antibody.
Researchers gave the antibody treatment to those with multidrug-resistant HIV along with an optimized antiretroviral regimen.
Nelson Vergel pushes for the development of new salvage therapies.
The Food and Drug Administration approves antibody treatment Trogarzo for multidrug-resistant HIV.
With an FDA decision for ibalizumab pending, data about a group with multidrug resistance show that the antibody is effective.
TaiMed Biologics has applied for approval of the weekly injectable antibody ibalizumab for people with multidrug-resistant virus.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.